31 completed, 26 recruiting, 18 unknown, 16 terminated. 49 Phase 2, 33 Phase 1, 20 Not applicable, 5 Phase 3.
Follow Colorectal Adenocarcinoma: new trials by email Literature Review of Colorectal Adenocarcinoma trials Research Report on Colorectal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial Balstilimab, Biopsy Procedure, Biospecimen Collection - Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2027-05-25 | 2026-09-29 |
| Exploratory Evaluation of the BiP Inhibitor BPR001-615 in Primary Cells and the Diagnostic Value of Circulating BiP in Colorectal Adenocarcinomas BPR001-615 - Colorectal Adenocarcinoma | Not applicable | Recruiting | Centre Hospitalier Universitaire de Nice | 15 | 2026-10-01 | 2026-09-17 |
| Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation Fludarabine, Cyclophosphamide, NW-301V - Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Not yet recruiting | Neowise Biotechnology | 66 | 2026-10-01 | 2026-10-15 |
| A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum VVD-133214, Pembrolizumab - Colorectal Adenocarcinoma | Phase 2 | Recruiting | Vividion Therapeutics, Inc. | 140 | 2026-09-11 | 2026-10-21 |
| TLR9 Immunotherapy for Peritoneal Carcinomatosis ACM-CpG - Malignant Ascites, Colorectal Adenocarcinoma | Phase 1 | Recruiting | Brown University | 24 | 2026-08-25 | 2026-10-01 |
| Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) Paclitaxel Q2W, Paclitaxcel Q3W - Esophageal Carcinoma, Gastric Cancer (Diagnosis) | Phase 2 | Recruiting | University of California, Irvine | 55 | 2026-08-04 | 2026-08-31 |
| Breath Research Narrow Validation for Gastrointestinal Cancer Detection Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma | Recruiting | Imperial College London | 1000 | 2026-07-26 | 2026-10-22 | |
| Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer Serplulimab + Decitabine + CAPOX (Oxaliplatin + Capecitabine) - Locally Advanced Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 35 | 2026-06-30 | 2026-07-09 |
| Evaluation of Skin Tests in Biotherapy Allergies Drug skin tests (investigating hypersensitivity to a biotherapy) - Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms | Not applicable | Recruiting | University Hospital, Angers | 70 | 2026-06-17 | 2026-06-18 |
| Family Communications After Genetic Testing Biospecimen Collection, Genetic Testing, Communication Intervention - Colon Adenocarcinoma, Colorectal Adenocarcinoma | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 4186 | 2026-04-06 | 2026-10-02 |
| Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes Blood will be drawn from 2 additional tubes of 5 ml each - Colorectal Adenocarcinoma | Not applicable | Recruiting | CHU de Reims | 650 | 2026-04-02 | 2026-04-09 |
| A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis Mass-based response testing (MRT) - Appendiceal Cancer, Colorectal Adenocarcinoma | Not applicable | Recruiting | Yale University | 20 | 2026-02-17 | 2026-07-21 |
| Study Comparing the Quality of Colon Cleanliness With Prepackaged LRD (Low-residue Diet) vs. Guided (POG). Colonoscopy, Questionnaires, Pre-colonoscopy diet according to the investigator's oral instructions - Colorectal Cancer Prevention, Colorectal Cancer (Diagnosis) | Not applicable | Not yet recruiting | Clinique Paris-Bercy | 230 | 2026-01-30 | 2026-02-17 |
| Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. Trastuzumab-Deruxtecan (T-DXd), Capecitabine, Bevacizumab - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 42 | 2025-10-20 | 2026-02-17 |
| Evaluation of Tumor Budding In Colorectal Adenocarcinoma Biological: Immunohistochemical staining - Colorectal Adenocarcinoma | Not yet recruiting | Sohag University | 50 | 2025-10-01 | 2025-06-04 | |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) - Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 150 | 2025-08-22 | 2026-09-17 |
| AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer AK112, Oxaliplatin, Irinotecan - Colorectal Adenocarcinoma | Phase 3 | Recruiting | Akeso | 560 | 2025-05-27 | 2026-03-04 |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| AK129 Combination Therapy for Advanced Solid Tumors AK129(dose 1), Pemetrexed, Paclitaxel - Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 / Phase 2 | Recruiting | Akeso | 230 | 2025-05-21 | 2025-06-03 |
| Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer Fluoxetine - Colorectal Adenocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 10 | 2025-03-20 | 2026-08-20 |
Showing 20 of 114. Sign in to see all of them.
Colorectal Neoplasms (66) · Colonic Neoplasms (19) · Rectal Neoplasms (13) · Pancreatic Neoplasms (12) · Neoplasm Metastasis (9) · Carcinoma, Hepatocellular (8) · Carcinoma, Non-Small-Cell Lung (7) · Neoplasms (7) · Carcinoma, Renal Cell (6) · Cholangiocarcinoma (6) · Squamous Cell Carcinoma of Head and Neck (6) · Adenocarcinoma Of Esophagus (5) · Stomach Neoplasms (5) · Breast Neoplasms (4) · Disease (4)
Neoplasms by Site (84) · Neoplasms (82) · Digestive System Diseases (78) · Digestive System Neoplasms (78) · Gastrointestinal Diseases (74) · Gastrointestinal Neoplasms (71) · Intestinal Diseases (71) · Intestinal Neoplasms (71) · Colonic Diseases (68) · Rectal Diseases (68) · Neoplasms by Histologic Type (27) · Neoplasms, Glandular and Epithelial (25) · Carcinoma (24) · Pathological Conditions, Signs and Symptoms (22) · Pathologic Processes (20)
Bevacizumab (14) · Capecitabine (11) · Oxaliplatin (11) · Fluorouracil (10) · Irinotecan (9) · Leucovorin (9) · Nivolumab (8) · Cetuximab (6) · pembrolizumab (5) · Cisplatin (3) · Cyclophosphamide (3) · Drug Therapy (3) · durvalumab (3) · trifluridine tipiracil drug combination (3) · Blood Specimen Collection (2)
National Cancer Institute (NCI) (6) · City of Hope Medical Center (5) · Emory University (4) · M.D. Anderson Cancer Center (4) · A2 Biotherapeutics Inc. (3) · University of Southern California (3) · Akeso (2) · Alliance for Clinical Trials in Oncology (2) · Federation Francophone de Cancerologie Digestive (2) · Imperial College London (2) · MiWEndo Solutions S.L. (2) · University of Aarhus (2) · Academic and Community Cancer Research United (1) · Achieve Life Sciences (1) · Aktis Oncology, Inc. (1)
United States (61) · China (16) · Spain (14) · France (13) · Italy (9) · United Kingdom (6) · Germany (4) · Netherlands (4) · Belgium (3) · Japan (3) · Puerto Rico (3) · Canada (2) · Denmark (2) · Hong Kong (2) · Israel (2)
Ajay Goel, PhD (5) · John Welch, MD, PhD (2) · Michael Schickler, PhD (2) · Afsaneh Barzi, MD (1) · Agnieszka Michael (1) · Alexandra R Brandt-Kerkhof, MD (1) · Alexis Leal, MD (1) · Ardaman S. Shergill, MD (1) · Arend G Aalbers, MD (1) · Arvind Dasari (1) · Babar Bashir, MD (1) · Catherine H Davis, MD (1) · Cathrine Nielsen, PhD (1) · Chandrikha Chandrasekharan, MD (1) · Charles S. Fuchs, MD, MPH (1)
PMID 10623705, PMID 12010363, PMID 19457245, PMID 2418689, PMID 24595805, PMID 26179333, PMID 26240218, PMID 27831501, PMID 29199088, PMID 29556198, PMID 29622799, PMID 30603797, PMID 30793712, PMID 30797795, PMID 31023318, PMID 31557064, PMID 31914032, PMID 32079180, PMID 32334940, PMID 33528867, PMID 33538338, PMID 33819484, PMID 34009291, PMID 34725214, PMID 35063964, PMID 35099776, PMID 35143424, PMID 35263150, PMID 35380713, PMID 35394982, PMID 35803311, PMID 36200668, PMID 36240854, PMID 36609320, PMID 36754451, PMID 37004094, PMID 37265425, PMID 37852737, PMID 38336371, PMID 38564700, PMID 38697893, PMID 39238638, PMID 39267685, PMID 39755582, PMID 40544180, PMID 41364052, PMID 41604539, PMID 42372745, PMID 42420958, PMID 42545685
P30CA014089 (3), P30CA138292 (3), P30CA015083 (2), 2016 (1), 2023 (1), P30CA015704 (1), P30CA046934 (1), R01CA166161 (1), U10CA180821 (1), UM1CA186688 (1)